Alpha DNA Investment Management LLC Makes New $411,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Alpha DNA Investment Management LLC bought a new stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 12,843 shares of the company's stock, valued at approximately $411,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its holdings in shares of SpringWorks Therapeutics by 48.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,110,462 shares of the company's stock valued at $202,318,000 after purchasing an additional 1,333,892 shares in the last quarter. Duquesne Family Office LLC acquired a new position in shares of SpringWorks Therapeutics in the second quarter worth $38,475,000. Maverick Capital Ltd. grew its stake in SpringWorks Therapeutics by 36.3% during the 2nd quarter. Maverick Capital Ltd. now owns 2,600,524 shares of the company's stock worth $97,962,000 after purchasing an additional 691,894 shares in the last quarter. Vanguard Group Inc. grew its position in shares of SpringWorks Therapeutics by 8.2% during the first quarter. Vanguard Group Inc. now owns 6,529,325 shares of the company's stock worth $321,373,000 after buying an additional 492,783 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in SpringWorks Therapeutics by 102.5% in the third quarter. Principal Financial Group Inc. now owns 918,445 shares of the company's stock worth $29,427,000 after acquiring an additional 464,903 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 4th. Evercore ISI assumed coverage on shares of SpringWorks Therapeutics in a research report on Wednesday, November 20th. They set an "outperform" rating and a $60.00 price objective on the stock. Wedbush reissued an "outperform" rating and issued a $77.00 target price on shares of SpringWorks Therapeutics in a report on Monday, November 18th. Finally, HC Wainwright dropped their price target on shares of SpringWorks Therapeutics from $76.00 to $74.00 and set a "buy" rating on the stock in a research note on Tuesday, November 12th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $67.00.

SpringWorks Therapeutics Price Performance

SpringWorks Therapeutics stock traded up $0.37 during midday trading on Monday, hitting $39.39. 1,551,781 shares of the stock were exchanged, compared to its average volume of 1,004,748. SpringWorks Therapeutics, Inc. has a 1 year low of $20.19 and a 1 year high of $53.92. The company has a 50 day moving average price of $32.68 and a two-hundred day moving average price of $36.71. The firm has a market cap of $2.93 billion, a P/E ratio of -10.15 and a beta of 0.79.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.03. The company had revenue of $49.10 million for the quarter, compared to the consensus estimate of $53.28 million. SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. SpringWorks Therapeutics's quarterly revenue was up 4810.0% compared to the same quarter last year. During the same quarter last year, the business posted ($1.27) EPS. As a group, analysts predict that SpringWorks Therapeutics, Inc. will post -3.12 EPS for the current year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.